The size of the North America Blood Testing Market has been calculated at USD 19.90 billion in 2022. It is further estimated to be growing at a CAGR of 2.32% and worth USD 22.32 billion by 2027.
Rising government initiatives and increasing the number of surgical procedures in North America are the factors propelling the demand for blood tests in this region.
Demand for blood is endlessly increasing with patients undergoing complex surgeries that involve blood transfusions. For patients' support, countries are growing their healthcare treatment so that the maximum number of people can benefit from the required treatment.
Increasing concerns about the spread of infectious diseases through donated blood has augmented the demand for blood and blood products. With the boost in the geriatric population and incidence of diseases, there is a rise in blood testing in developed regions such as North America. The cost of blood handling equipment is a key challenge faced by the blood testing market.
This research report on the North America Blood Testing Market has been segmented and sub-segmented into the following categories:
Based on the region, the USA is leading the region’s market in terms of revenue, followed by Canada.
Promising Companies dominating the North America Blood Testing Market profiled in the report are Bio-Rad Laboratories Inc. (U.S.), Siemens Healthcare (Germany), Grifols (Spain), Nanosphere Inc. (U.S.), BioMérieux (France), Dickinson and Company (U.S.), Ortho Clinical Diagnostics Inc. (U.S.), Roche Diagnostics (Switzerland), Alere Inc. (U.S.), Bruker Corporation (U.S.), Abbott Laboratories (U.S.), Thermo Fisher Scientific Inc. (U.S.) and Beckman Coulter (U.S.).